Militia Capital Management LLC Invests $1.65 Million in TransMedics Group, Inc. $TMDX

Militia Capital Management LLC acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 1st quarter, Holdings Channel reports. The fund acquired 16,600 shares of the company’s stock, valued at approximately $1,650,000.

Other large investors also recently modified their holdings of the company. Hussman Strategic Advisors Inc. purchased a new stake in TransMedics Group in the 4th quarter worth $1,788,000. Baillie Gifford & Co. raised its holdings in TransMedics Group by 21.4% during the fourth quarter. Baillie Gifford & Co. now owns 316,473 shares of the company’s stock valued at $38,499,000 after acquiring an additional 55,754 shares during the period. Candriam S.C.A. lifted its position in shares of TransMedics Group by 45.4% in the first quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock valued at $15,783,000 after acquiring an additional 49,580 shares in the last quarter. M&T Bank Corp lifted its position in shares of TransMedics Group by 749.2% in the fourth quarter. M&T Bank Corp now owns 18,572 shares of the company’s stock valued at $2,259,000 after acquiring an additional 16,385 shares in the last quarter. Finally, Zevenbergen Capital Investments LLC boosted its stake in shares of TransMedics Group by 8.4% in the fourth quarter. Zevenbergen Capital Investments LLC now owns 280,178 shares of the company’s stock worth $34,084,000 after acquiring an additional 21,655 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Down 4.2%

TMDX opened at $71.20 on Thursday. The company has a market capitalization of $2.46 billion, a PE ratio of 16.18 and a beta of 1.89. The firm has a 50-day simple moving average of $71.37 and a two-hundred day simple moving average of $103.42. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. TransMedics Group, Inc. has a 52 week low of $60.10 and a 52 week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). The firm had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same period last year, the firm posted $0.70 earnings per share. Analysts forecast that TransMedics Group, Inc. will post 1.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on TMDX shares. Oppenheimer downgraded TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 6th. Stifel Nicolaus upped their price target on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research note on Thursday, June 18th. Needham & Company LLC cut their price objective on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Canaccord Genuity Group reiterated a “buy” rating and set a $124.00 price objective on shares of TransMedics Group in a research report on Tuesday, June 30th. Finally, TD Cowen reissued a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a report on Wednesday, July 1st. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $134.50.

Insiders Place Their Bets

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares in the company, valued at $1,249,148.52. This trade represents a 36.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by corporate insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.